Sanofi-Aventis up after generic blocked
693013
A U.S. judge has granted a request from  Sanofi-Aventis and U.S. partner Bristol-Myers Squibb Co.   to block the sale in the United States of a generic  form of its top selling blood-thinner Plavix, giving a boost to  shares in the French drugmaker on Friday.
587421
Investors kept their eye on makers of generic pharmaceuticals Monday with news that Mylan Laboratories Inc. received Food and Drug Administration approval to market a generic version of a Novartis AG hypertension
731856
British regulators recommended that physicians restrict the use of the anti-depressant Efexor because its use could have side effects for heart health and pose other risks that require more careful monitoring than its competitors. The drug's manufacturer, Wyeth, said it would challenge the decision, but its shares slipped 3 percent.
658531
A federal appeals court has cleared  the way for Alpharma Inc. ALO.N to launch a generic form of  Pfizer Inc.'s PFE.N Neurontin capsules to treat epilepsy,  sending Alpharma shares sharply higher.
226791
A court ruling upholding the  patent on blockbuster blood-thinning drug Plavix has reignited  talk France&#39;s Sanofi-Aventis  will bid for its smaller  U.S. partner Bristol-Myers Squibb Co. .
97646
The Motley Fool - As investors waited anxiously for Amgen's (Nasdaq: AMGN - News) earnings report, the United Kingdom's high court snuck in with a stinker. It ruled that Transkaryotic Therapies (Nasdaq: TKTX - News) and Sanofi-Aventis (NYSE: SNYT - News) did not infringe on the patent for EPO, Amgen's anemia treatment (which accounts for 27% of its sales), and ruled the patent invalid.
557
TRENTON, N.J. -- A federal court invalidated the patent yesterday for Merck &amp; Co.'s second-largest-selling drug, the blockbuster osteoporosis treatment Fosamax, in a decision that offers millions of patients hope for a cheaper version sooner, but darkens the company's already clouded outlook.
596613
Sanofi-Aventis SA, the world&#39;s third- largest drugmaker, said predecessor company Sanofi-Synthelabo SA&#39;s first-half profit rose 21 percent, helped by demand for the blood thinner Plavix and the cancer treatment Eloxatin.
310124
Two generic drug products by the Indian  drug maker Cipla for treating HIV/AIDS have been reinstated on  the World Health Organization's recommended list six months  after being removed, a senior WHO official said on Tuesday.
438884
Drugmaker Sanofi-Aventis , the  target of a lawsuit seeking class-action status filed on behalf  of shareholders, on Friday vowed to fight allegations it hid  the side-effects of its anti-obesity drug Acomplia.
145102
Scientists find the answer to stopping the virus might be right under their noses -- generic antipsychotic medications. By Serena Gordon.
311254
Expectations rose for Sanofi-Aventis's  big new drug hope Acomplia on Friday as the French firm  revealed it would present two-year, rather than one-year, data  on the anti-obesity medicine next week.
335426
The newly formed pharmaceutical group Sanofi-Aventis published third-quarter sales figures showing a 10.7 percent increase over 12 months in line with expectations.
596137
Sanofi-Synthelabo said earlier this month it would push for 100 percent control of its former rival and newly-acquired subsidiary Aventis after the French Financial Market Authority confirmed the success of its ...
115938
Alpharma Inc. ALO.N on Friday began  selling a cheaper generic version of Pfizer Inc.'s PFE.N $3  billion a year epilepsy drug Neurontin without waiting for a  court ruling on Pfizer's request to block the copycat medicine.
151529
A U.S. judge on Thursday granted a  request from Sanofi-Aventis  and Bristol-Myers Squibb  Co.  to block the sale of a generic form of their  top-selling Plavix blood thinner.
364253
PARIS Sanofi-Aventis shares rose Monday after the French-German drugmaker reported a clinical study showing its experimental anti-obesity drug succeeded in helping people lose weight.